Myelodysplastic syndromes display a high degree of heterogeneity, making it difficult to establish a standard of care for patients.
Transfusion independence for at least 8 weeks was observed in 38% of patients receiving luspatercept compared with 13% of patients receiving placebo.
Rates of nonrelapse mortality and 3-year overall survival were similar between patients 55 to 64 years old and patients 65 years or older who underwent transplantation.
Researchers conducted a meta-analysis to determine whether iron chelation therapy leads to improved overall and leukemia-free survival in patients with myelodysplastic syndrome.
Transfusion dependence, very high-risk cytogenetics, and high serum ferritin were identified as risk factors for death in a multivariable analysis.
Researchers identified 8 combinations of genes that could be used to predict whether a patient will respond to treatment with hypomethylating agents.
Nonmyeloablative conditioning was associated with increased nonrelapse mortality and shorter overall survival compared with reduced-intensity conditioning.
Patients who received androgen therapy demonstrated improvements in erythroid, platelet, and neutrophil measures.
The rate of 5-year overall survival in patients with myelodysplastic syndrome who underwent second allogeneic hematopoietic stem cell transplantation was 25.3%.
A variety of immune pathways mediate the pathogenesis of myelodysplastic syndromes, suggesting that the immune system may be a feasible therapeutic target.
Compared with hypomethylating agents, intensive chemotherapy was associated with higher overall response and complete remission rates.
Patients who experienced reactivation of Epstein-Barr virus also experienced inferior relapse-free survival and increased incidence of relapse.
Results from a systematic review and meta-analysis published in Critical Reviews in Oncology/Hematology indicated there was no association between mutations in SF3B1 and overall survival (OS) in patients with myelodysplastic syndrome (MDS). Mutations in the SF3B1 gene are the most common mutations in MDS, though the prognostic implications of these mutations are unclear. In this…
Prolonged-release administration of anagrelide resulted in a noninferior decrease in mean platelet levels compared with immediate-release administration.
There is a pressing need to develop novel therapeutic strategies for patients with myelodysplastic syndrome who are ineligible for transplantation.
The current set of standardized treatment response criteria was most recently revised in 2006 and had many shortcomings when applied to clinical trials.
Up to 65% of patients with myelodysplastic syndrome experience comorbid thrombocytopenia.
Immunosuppressive therapy is used sparingly due to the operational challenges in administration and prediction of patient benefit.
The presence of persistent disease-related mutations 30 days after ASCT for myelodysplastic syndrome was associated with higher risk of disease progression.
In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.
A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.
What is the concern behind PARP inhibitors and leukemia?
Smoking may slightly increase the risk for myelodysplastic syndromes, but alcohol consumption may be significantly protective against MDS.
The US Food and Drug Administration granted orphan drug designation to DSP-7888 for myelodysplastic syndrome.
The results of this study suggest that RIC may be an alternative to MAC, particularly for patients of low cytogenetic risk.
Based on the results of this study, an alternative to HCT should be considered for patients with CK and mutations in TP53 or the RAS pathway.
Eltrombopag was well-tolerated, significantly raised platelet counts, and reduced bleeding events among patients with MDS and severe thrombocytopenia.